Day 1 :
Keynote Forum
William J. Rowe
Former Assistant Clinical Professor of Medicine, Medical University of Ohio at Toledo,USA
Keynote: Hypertension risk from iron brake particulate matter
Biography:
William J. Rowe M.D. FBIS (Fellow British Interplanetary Society), FACN (Fellow American College of Nutrition, Retired Fellow Royal Society of Medicine), is a board certified specialist in Internal Medicine. He received his M.D. at the University of Cincinnati and was in private practice in Toledo, Ohio for 34 years. This triggered a 20 year pursuit of the cardiovascular complications of Space flight. He has published in LANCET that extraordinary, unremitting endurance exercise can injure a perfectly normal heart. Of only 4 space syndromes, he has published 2: "The Apollo 15 Space Syndrome" and "Neil Armstrong Syndrome."
Abstract:
Of 12 moon walkers, James Irwin on day after return from Apollo 15 mission, showed extraordinary bicycle ( B) stress test (ST) hypertension ( 275/125) after 3 minutes exercise; supervising > 5000 maximum treadmill ST, author never witnessed ST- blood pressure approaching this level. Symptom-limited maximum B stress test showed “cyanotic fingernails”; possibly venous blood trapped peripherally, supporting author’s “Apollo 15 Space Syndrome,” postulating that severe fingertip pain during space walks, triggered by plasma fluid, trapped distally; mechanism could be related to endothelial dysfunction, providing “silent ischemia” warning. Neil Armstrong returned to Earth with severe diastolic hypertension ( 160/135), consistent with ischemic left ventricular dysfunction; 50 mm increase in comparison with resting BP 110/85. With inhalation of lunar dust, brought into habitat on space suit, with high lunar iron (I) this dust inhalation, along with reduced (R) space flight- transferrin, R antioxidant, calcium (Ca) blocker - magnesium, conducive to severe oxidative stress, Ca overload with potential endothelial injuries. Using moon walker studies as example, my recent editorials show that I dust, released from brakes, with over 90% of brakes made of I, is a major hypertension factor and may also contribute to myocardial infarctions.
Keynote Forum
William J. Rowe
Former Assistant Clinical Professor of Medicine, Medical University of Ohio at Toledo,USA
Keynote: Hypertension risk from iron brake particulate matter
Time : 9.00:9:45
Biography:
William J. Rowe M.D. FBIS (Fellow British Interplanetary Society), FACN (Fellow American College of Nutrition, Retired Fellow Royal Society of Medicine), is a board certified specialist in Internal Medicine. He received his M.D. at the University of Cincinnati and was in private practice in Toledo, Ohio for 34 years. This triggered a 20 year pursuit of the cardiovascular complications of Space flight. He has published in LANCET that extraordinary, unremitting endurance exercise can injure a perfectly normal heart. Of only 4 space syndromes, he has published 2: "The Apollo 15 Space Syndrome" and "Neil Armstrong Syndrome."
Abstract:
Of 12 moon walkers, James Irwin on day after return from Apollo 15 mission, showed extraordinary bicycle ( B) stress test (ST) hypertension ( 275/125) after 3 minutes exercise; supervising > 5000 maximum treadmill ST, author never witnessed ST- blood pressure approaching this level. Symptom-limited maximum B stress test showed “cyanotic fingernails”; possibly venous blood trapped peripherally, supporting author’s “Apollo 15 Space Syndrome,” postulating that severe fingertip pain during space walks, triggered by plasma fluid, trapped distally; mechanism could be related to endothelial dysfunction, providing “silent ischemia” warning. Neil Armstrong returned to Earth with severe diastolic hypertension ( 160/135), consistent with ischemic left ventricular dysfunction; 50 mm increase in comparison with resting BP 110/85. With inhalation of lunar dust, brought into habitat on space suit, with high lunar iron (I) this dust inhalation, along with reduced (R) space flight- transferrin, R antioxidant, calcium (Ca) blocker - magnesium, conducive to severe oxidative stress, Ca overload with potential endothelial injuries. Using moon walker studies as example, my recent editorials show that I dust, released from brakes, with over 90% of brakes made of I, is a major hypertension factor and may also contribute to myocardial infarctions.
Keynote Forum
Samer H. Ellahham
Cleveland Clinic, USA and Cleveland Clinic Abu Dhabi, UAE
Keynote: The nuts and bolts of an inpatient cardio-oncology consult team
Time : 10.30-11.30
Biography:
Dr. Ellahham received his undergraduate degree in biology and his M.D. from the American University of Beirut, Beirut, Lebanon. Dr Ellahham finished his internal medicine residency in Georgetown University Hospital - Washington Hospital Center and his fellowship in Cardiology at the Virginia Commonwealth University Health System in USA. Dr. Ellahham worked in Washington DC in Georgetown University Hospital - Washington Hospital Center and in several clinical and leadership positions before moving to UAE in 2008. Dr. Ellahham continues to be an active clinician. He demonstrates great skill and experience in the management of patients with heart failure, ischemic heart disease, and valvular heart disease and led a multi-disciplinary team in the care and delivery of advanced therapies to these patients. He has unique abilities to partner and engage local and regional referring providers. He can work in a highly matrixed environment, possess strong leadership and organizational skills and have experience to working effectively in a large health system. He led the First AHA GWTG Heart Failure Initiative outside US and was the recipient of the AHA GWTG Award in Wash. DC. He is the champion of the AHA GWTG in the region. Dr. Ellahham has served as Chief Quality Officer for SKMC from 2009 till 2017. In his role, he has led the development of a quality and safety program that has been highly successful and visible and has been recognized internationally by several awards. As Chief Quality Officer and Global Healthcare Leader, he had a focus on ensuring that implementation of these best practices leads to breakthrough improvements in clinical quality, patient safety, patient experience and risk management.
Abstract:
Cancer is a global burden. By the year 2030, 23.6 million new cancer cases are expected to be added annually to the global burden. Traditional cancer treatment such as anthracycline-based chemotherapies, monoclonal antibody-based therapies (e.g. trastuzumab), and radiation can have cardiac toxicities. In the last decade, novel cancer therapies or their combinations have improved cancer survivorship. These cancer therapies are associated with cardiovascular complications. Additionally, cancer patients and survivors are often elderly and have new or preexisting cardiovascular comorbidities. Patients with pre-existing cardiovascular disease have an increased risk of cardiovascular toxicity. Cardiovascular complications of cancer therapy have a profound negative effect on the survival and quality of life of cancer patients. Cancer therapies can affect the whole cardiovascular system but generally, these cardiotoxic effects are reported as changes in left ventricular (LV) ejection fraction. The most common cardiovascular adverse effects are LV dysfunction and heart failure (HF). Other adverse effects include hypertension, acute coronary syndromes, thromboembolic events, rhythm disturbances, valvular and/or pericardial disease. Hence, prediction, early recognition and timely management of cardiovascular complications in cancer patients is gaining importance. This need gave birth to the concept of interdisciplinary cardiology-oncology (cardio-onco) care delivered through a team of cardiologists, oncologists and hematologists. The cardio-onco care model is a relatively new field. Clinicians often face the dilemma as to whether give preference to the cancer status of the patient or to the cardiovascular toxicity. Lack of awareness about this integrated practice, its availability in very few centers, lack of proper protocols for decision making and resources to set up such a team are some of the key challenges in implementing the cardio-oncology program Oncologists, nurses, patients and their attendants should be trained to recognize signs and symptoms of cardiotoxicity.
Keynote Forum
Dr. Sudha Bansode
University of California, Riverside, USA.
Keynote: Heart disease
Time : 11.30-12.30
Biography:
Dr. Sudha Bansode is a Associate Professor in Zoology at Shankarrao Mohite College, Akluj, Maharashtra State, India. Recently she has completed her Post Doctoral Studies at University of California, Riverside, USA. She is a active researcher & passionate teacher in India. Still she has been published above 35 research papers in International Journals & she is interested on Bone Research. Also she has honour of Distinguished Editorial Board Member of several International Journals. She is a own author of “Textbook Histological Techniques” & “Outlines of Physiology”. And now she is working on another own reference book “Rhythms in Freshwater Crustaceans”. She is a University recognized research guide for Ph.D. students in India.She was a invited Indian Speaker of “OXFORD SYMPOSIUM” on 27-29 August, 2014 at Balliol College, Oxford, United Kingdom & CELL SIGNALING & CANCER THERAPY – International Conference at Double Tree, Hilton Chicago on 27-28 September 2017, Genetics, Cell and Gene Therapy at Amsterdam, Netherlands, Sweden, Canada etc. She was academic visitor of Bangkok- Thailand, Colombo-Sri Lanka, Daira-Dubai-UAE. Her recent intellectual Interaction is with many International Professional groups.
Abstract:
There are many factors that can increase your risk of getting heart disease. Some of these factors are out of your control, but many of them can be avoided by choosing to live a healthy lifestyle. Some of the risk factors you cannot control are: Gender, Age, Family History, Obesity, High Cholesterol, Smoking, High Blood Pressure, Diabetes, Other factors.Heart disease is the leading cause of death. The causes and prevention of heart disease have been studied for years, and new information is emerging. For the last several decades, saturated fat and cholesterol have been thought to be major contributors to coronary artery disease, and therefore people are typically advised to strictly limit these in their diet. However, recent studies are indicating that it may not be wise to strictly limit the intake of dietary saturated fatty acids or replace them with polyunsaturated fatty acids when taking other health conditions into consideration. Depending on a person’s genetics, diet may or may not be an important factor in preventing heart disease. Exercise is also beneficial for everyone in preventing heart disease. When considering human development, including the negative effects of heart disease, humans still have a lot to learn about the human body and the interaction of diet, the environment, and genetics.